Zacks Investment Research downgraded shares of Concert Pharmaceuticals (NASDAQ:CNCE) from a hold rating to a sell rating in a report issued on Friday morning.

According to Zacks, “Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small molecule drugs. The Company manufactures drugs in various therapeutic areas such as hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, and schizophrenia, multiple tumors, and hyperparathyroidism. Concert Pharmaceuticals Inc. is based in United States. “

Get Concert Pharmaceuticals alerts:

A number of other research analysts have also issued reports on the stock. BidaskClub lowered shares of Concert Pharmaceuticals from a strong-buy rating to a buy rating in a research note on Friday, December 22nd. UBS Group set a $34.00 price target on shares of Concert Pharmaceuticals and gave the stock a buy rating in a research note on Tuesday, December 19th. Mizuho lowered shares of Concert Pharmaceuticals from a buy rating to a neutral rating and set a $23.00 price target on the stock. in a research note on Friday, January 12th. Stifel Nicolaus restated a buy rating and set a $27.00 target price on shares of Concert Pharmaceuticals in a research report on Friday, January 12th. Finally, TheStreet upgraded shares of Concert Pharmaceuticals from a d rating to a c+ rating in a research report on Wednesday, November 29th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $25.00.

Concert Pharmaceuticals (NASDAQ:CNCE) opened at $22.59 on Friday. Concert Pharmaceuticals has a one year low of $9.50 and a one year high of $30.71.

Concert Pharmaceuticals (NASDAQ:CNCE) last issued its quarterly earnings results on Thursday, March 1st. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.08). Concert Pharmaceuticals had a negative return on equity of 36.25% and a net margin of 66.47%. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $8.11 million. sell-side analysts anticipate that Concert Pharmaceuticals will post -2.35 earnings per share for the current year.

In other Concert Pharmaceuticals news, Director Richard Aldrich sold 31,236 shares of the company’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $19.14, for a total transaction of $597,857.04. Following the transaction, the director now directly owns 286,975 shares in the company, valued at $5,492,701.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Value Fund L. P. Biotechnology sold 1,282,856 shares of the company’s stock in a transaction dated Tuesday, December 19th. The stock was sold at an average price of $26.65, for a total transaction of $34,188,112.40. The disclosure for this sale can be found here. Insiders have sold 1,419,092 shares of company stock worth $36,876,675 over the last 90 days. 10.10% of the stock is currently owned by company insiders.

Several hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. grew its position in shares of Concert Pharmaceuticals by 57.2% in the fourth quarter. BlackRock Inc. now owns 1,786,223 shares of the biotechnology company’s stock valued at $46,210,000 after purchasing an additional 649,808 shares during the last quarter. Ingalls & Snyder LLC grew its position in shares of Concert Pharmaceuticals by 8.7% in the fourth quarter. Ingalls & Snyder LLC now owns 1,314,562 shares of the biotechnology company’s stock valued at $34,008,000 after purchasing an additional 105,500 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Concert Pharmaceuticals by 11.0% in the second quarter. Vanguard Group Inc. now owns 756,513 shares of the biotechnology company’s stock valued at $10,553,000 after purchasing an additional 74,801 shares during the last quarter. Millennium Management LLC grew its position in shares of Concert Pharmaceuticals by 225.8% in the fourth quarter. Millennium Management LLC now owns 725,885 shares of the biotechnology company’s stock valued at $18,779,000 after purchasing an additional 503,066 shares during the last quarter. Finally, Lyon Street Capital LLC grew its position in shares of Concert Pharmaceuticals by 6.5% in the third quarter. Lyon Street Capital LLC now owns 463,064 shares of the biotechnology company’s stock valued at $6,830,000 after purchasing an additional 28,312 shares during the last quarter. Institutional investors and hedge funds own 71.74% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://www.watchlistnews.com/zacks-investment-research-lowers-concert-pharmaceuticals-cnce-to-sell/1909399.html.

About Concert Pharmaceuticals

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.